Cargando…

Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy

SIMPLE SUMMARY: With the prolonged survival of metastatic cancer patients, medium to long-term outcomes of local therapy for oligometastases are important and should be discussed. Metastasectomy is a reasonable treatment for isolated lesions when feasible. This retrospective study aimed to examine t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Satoshi, Demura, Satoru, Murakami, Hideki, Shinmura, Kazuya, Yokogawa, Noriaki, Annen, Ryohei, Kobayashi, Motoya, Yamada, Yohei, Nagatani, Satoshi, Kawahara, Norio, Tsuchiya, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221216/
https://www.ncbi.nlm.nih.gov/pubmed/35740517
http://dx.doi.org/10.3390/cancers14122852
_version_ 1784732565791309824
author Kato, Satoshi
Demura, Satoru
Murakami, Hideki
Shinmura, Kazuya
Yokogawa, Noriaki
Annen, Ryohei
Kobayashi, Motoya
Yamada, Yohei
Nagatani, Satoshi
Kawahara, Norio
Tsuchiya, Hiroyuki
author_facet Kato, Satoshi
Demura, Satoru
Murakami, Hideki
Shinmura, Kazuya
Yokogawa, Noriaki
Annen, Ryohei
Kobayashi, Motoya
Yamada, Yohei
Nagatani, Satoshi
Kawahara, Norio
Tsuchiya, Hiroyuki
author_sort Kato, Satoshi
collection PubMed
description SIMPLE SUMMARY: With the prolonged survival of metastatic cancer patients, medium to long-term outcomes of local therapy for oligometastases are important and should be discussed. Metastasectomy is a reasonable treatment for isolated lesions when feasible. This retrospective study aimed to examine the medium to long-term outcomes of spinal metastasectomy in 124 patients with isolated spinal metastases who underwent metastasectomy. The primary malignancy was renal cell carcinoma in 51 patients, thyroid carcinoma in 14 patients, low-grade sarcoma in 13 patients, lung cancer in 13 patients, breast cancer in 12 patients, and other malignancies in 21 patients. The 3-year and 5-year survival rates were 70% and 60%, respectively. Patients with thyroid cancer had the best survival results. The occurrence rates for the local recurrence of the operated spinal lesion and instrumentation failure were 10% and 22%, respectively. For certain patients with isolated and removable spine metastases, metastasectomy can be a useful treatment option. ABSTRACT: The prolonged survival of metastatic cancer patients highlights the importance of the local control of spinal metastases, which reduce patient performance status. This retrospective study examined the medium to long-term outcomes of spinal metastasectomy by evaluating 124 patients who underwent metastasectomy for isolated spinal metastases (2006–2018) with a postoperative follow-up for a minimum of 3 years. The findings present information on patient demographics (i.e., performance status, location of non-spinal metastases, and history of systemic therapy) and postoperative outcomes, including perioperative complications, disease progression of non-operated metastases, and additional excisional surgeries. Additionally, postoperative survival, local tumor control in the operated spine, and maintenance of spinal reconstruction without instrumentation failure were determined using Kaplan–Meier analyses. The primary malignancy was kidney and thyroid cancer in 51 and 14 patients, respectively, low-grade sarcoma and lung cancer in 13 patients, breast cancer in 12 patients, and other malignancies in 21 patients. The 3-year and 5-year survival rates were 70% and 60%, respectively. We found that patients with thyroid cancer had the best survival results, with local tumor recurrence and instrumentation failure at 10% and 22%, respectively. These findings suggest that for certain patients with isolated and removable spine metastases, metastasectomy can improve function and survival.
format Online
Article
Text
id pubmed-9221216
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92212162022-06-24 Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy Kato, Satoshi Demura, Satoru Murakami, Hideki Shinmura, Kazuya Yokogawa, Noriaki Annen, Ryohei Kobayashi, Motoya Yamada, Yohei Nagatani, Satoshi Kawahara, Norio Tsuchiya, Hiroyuki Cancers (Basel) Article SIMPLE SUMMARY: With the prolonged survival of metastatic cancer patients, medium to long-term outcomes of local therapy for oligometastases are important and should be discussed. Metastasectomy is a reasonable treatment for isolated lesions when feasible. This retrospective study aimed to examine the medium to long-term outcomes of spinal metastasectomy in 124 patients with isolated spinal metastases who underwent metastasectomy. The primary malignancy was renal cell carcinoma in 51 patients, thyroid carcinoma in 14 patients, low-grade sarcoma in 13 patients, lung cancer in 13 patients, breast cancer in 12 patients, and other malignancies in 21 patients. The 3-year and 5-year survival rates were 70% and 60%, respectively. Patients with thyroid cancer had the best survival results. The occurrence rates for the local recurrence of the operated spinal lesion and instrumentation failure were 10% and 22%, respectively. For certain patients with isolated and removable spine metastases, metastasectomy can be a useful treatment option. ABSTRACT: The prolonged survival of metastatic cancer patients highlights the importance of the local control of spinal metastases, which reduce patient performance status. This retrospective study examined the medium to long-term outcomes of spinal metastasectomy by evaluating 124 patients who underwent metastasectomy for isolated spinal metastases (2006–2018) with a postoperative follow-up for a minimum of 3 years. The findings present information on patient demographics (i.e., performance status, location of non-spinal metastases, and history of systemic therapy) and postoperative outcomes, including perioperative complications, disease progression of non-operated metastases, and additional excisional surgeries. Additionally, postoperative survival, local tumor control in the operated spine, and maintenance of spinal reconstruction without instrumentation failure were determined using Kaplan–Meier analyses. The primary malignancy was kidney and thyroid cancer in 51 and 14 patients, respectively, low-grade sarcoma and lung cancer in 13 patients, breast cancer in 12 patients, and other malignancies in 21 patients. The 3-year and 5-year survival rates were 70% and 60%, respectively. We found that patients with thyroid cancer had the best survival results, with local tumor recurrence and instrumentation failure at 10% and 22%, respectively. These findings suggest that for certain patients with isolated and removable spine metastases, metastasectomy can improve function and survival. MDPI 2022-06-09 /pmc/articles/PMC9221216/ /pubmed/35740517 http://dx.doi.org/10.3390/cancers14122852 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kato, Satoshi
Demura, Satoru
Murakami, Hideki
Shinmura, Kazuya
Yokogawa, Noriaki
Annen, Ryohei
Kobayashi, Motoya
Yamada, Yohei
Nagatani, Satoshi
Kawahara, Norio
Tsuchiya, Hiroyuki
Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy
title Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy
title_full Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy
title_fullStr Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy
title_full_unstemmed Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy
title_short Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy
title_sort medium to long-term clinical outcomes of spinal metastasectomy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221216/
https://www.ncbi.nlm.nih.gov/pubmed/35740517
http://dx.doi.org/10.3390/cancers14122852
work_keys_str_mv AT katosatoshi mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT demurasatoru mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT murakamihideki mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT shinmurakazuya mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT yokogawanoriaki mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT annenryohei mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT kobayashimotoya mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT yamadayohei mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT nagatanisatoshi mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT kawaharanorio mediumtolongtermclinicaloutcomesofspinalmetastasectomy
AT tsuchiyahiroyuki mediumtolongtermclinicaloutcomesofspinalmetastasectomy